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The cannabinoid CB1 receptor (CB1R) is a G protein-coupled
receptor, which couples to theGi/o family of heterotrimeric G pro-
teins.The receptordisplays bothbasal andagonist-induced signal-
ing and internalization. Although basal activity of CB1Rs is attrib-
uted to constitutive (agonist-independent) receptor activity,
studies in neurons suggested a role of postsynaptic endocannabi-
noid (eCB) release in the persistent activity of presynaptic CB1Rs.
To elucidate the role of eCBs in basalCB1Ractivity, wehave inves-
tigated the role of diacylglycerol lipase (DAGL) in this process in
Chinese hamster ovary (CHO) cells, which are not targeted specif-
ically with eCBs. Agonist-induced G protein activation was deter-
mined by detecting dissociation G protein subunits expressed in
CHO cells with bioluminescence resonance energy transfer
(BRET), after labeling the and subunits with Renilla luciferase
andenhancedyellow fluorescentprotein (EYFP), respectively.Pre-
incubation of the cells with tetrahydrolipstatin (THL), a known
inhibitorofDAGLs, caused inhibitionof thebasal activityofCB1R.
Moreover, preincubation of CHO and cultured hippocampal neu-
rons with THL increased the number of CB1Rs on the cell mem-
brane, which reflects its inhibitory action onCB1R internalization
in non-simulated cells. In CHO cells co-expressing CB1R and
angiotensinAT1 receptors, angiotensin II-inducedGoproteinacti-
vationthatwasblockedbybothaCB1RantagonistandTHL.These
data indicate that cell-derivedeCBmediatorshave ageneral role in
the basal activity of CB1Rs in non-neural cells and neurons, and
that thismechanism can be stimulated byAT1 receptor activation.
The cannabinoid CB1 receptor (CB1R)2, a member of the G
protein-coupled receptor (GPCR) superfamily (1), is activated
by several lipid-derived endocannabinoid (eCB) ligands includ-
ing anandamide and 2-arachydonyl-glycerol (2-AG) (2, 3).
Anandamide production in cells is a phospholipase D-depend-
ent process, whereas 2-AG is generated by diacylglycerol
lipases (DAGLs) from diacylglycerol (DAG) (4). The receptor is
widely distributed in several tissues and is one of themost abun-
dant GPCRs in the brain, being predominantly localized in
axons of GABAergic neurons (5, 6). CB1R agonists are already
used in chemotherapy-induced nausea and vomiting of cancer
patients who have failed to respond adequately to conventional
antiemetic therapy, whereas CB1R antagonists have recently
been introduced in the therapy of obesity and nicotine addic-
tion (4). Furthermore, modulating CB1R activity has therapeu-
tical potential in awide range of pathological conditions includ-
ing mood and anxiety disorders, movement disorders,
neuropathic pain, and multiple sclerosis, as well as cancer, car-
diovascular diseases, obesity/metabolic syndrome, and muscu-
loskeletal disorders (4, 7). CB1R couplesmainly to theGi/o fam-
ily of heterotrimeric G proteins. However, recent data suggest
that it can also couple to Gq proteins (4). CB1Rs mediate retro-
grade signaling of activated neurons (4). Furthermore, in many
cellular systems non-stimulated CB1Rs produce constitutive
signal generation and internalization (8). Constitutive internal-
ization of CB1Rs has been reported both in HEK-293 cells and
in neurons (9, 10). This process can be blocked by inverse ago-
nists and is required for the correct axonal localization of
CB1Rs in neurons, which underlines the physiological impor-
tance of this process (10). Although these effects are generally
attributed to the constitutive activity of CB1Rs (8), continuous
stimulation by eCBs can serve as an alternative mechanism to
explain these data. Theoretically, a validated neutral CB1R
antagonist, i.e. an antagonist without inverse agonist activity
could arbitrate between these two alternative models, but no
such molecule has been generated for CB1Rs. Recent papers
proposed a role of continuous postsynaptic eCB release in the
persistent inhibition of inhibitory postsynaptic currents in hip-
pocampal and proopiomelanocortin neurons. This was shown
to be a homosynaptic effect, based on findings that chelation of
postsynaptic intracellularCa2withBAPTA interfereswith the
stimulatory effect of CB1R antagonists on presynaptic GABA
release (11, 12). Similar findings were also reported in basolat-
eral amygdala neurons (13). However, other studies showed
that constitutive activity of expressed CB1Rs can also be
detected in the absence of eCBs both in neurons andCHOcells,
suggesting that the receptor is constitutively active (8, 14–17).
Furthermore, constitutive internalization of CB1R is also
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detected in the somatodendritic region of isolated GABAergic
neurons (10), which cannot be explained by postsynaptic regu-
lation by cannabinoids and homosynaptic regulation.
To elucidate the intrinsic properties and the role of eCB
release in the basal signaling activity and internalization of
CB1Rs, we have expressed these receptors in CHO cells and
cultured primary hippocampal neurons and studied the role of
DAGLs in these processes. DAGLs are responsible for the pro-
duction of 2-AG and are widely expressed in most tissues (18).
Therefore, we tested whether the inhibition of this enzyme can
lead to interference with the basal activity of CB1R expressed in
CHO cells. During retrograde signaling CB1R activity in pre-
synaptic terminals can be regulated by eCB release caused by
Ca2 mobilizing agonists (4, 6). Since CB1R is expressed in
various cells of the cardiovascular system (19), we also tested
whether stimulation of co-expressed angiotensin AT1 recep-
tors (AT1Rs), which activate Gq, can increase the activity of
CB1Rs in CHO cells.
Using energy transfer measurements between heterotrim-
eric G protein subunits to detect G protein activation, here we
show that the basal activity of CB1R inCHOcells is inhibited by
THL, a known DAGL inhibitor. Basal CB1R internalization in
CHO cells and cultured primary hippocampal neurons is also
diminished following THL treatment. Moreover, we show that
CB1R is activated following AT1R stimulation in CHO cells,
and this activation is blocked by THL or a CB1R blocker. These
data suggest the role ofDAGLs in the basal activity of CB1R and
support the model where this activity is driven by eCBs.
EXPERIMENTAL PROCEDURES
Materials—Rat o-CFP G protein subunit was kindly pro-
vided by Dr. N. Gautam (20). Human 1 and 11 G protein
subunits were obtained from theUMR cDNAResource Center.
Coelenterazine h, fetal bovine serum (FBS), Opti-MEM, Lipo-
fectamine 2000, Neurobasal medium, and Versene were from
Invitrogen. Candesartanwas a gift fromAstraZeneca (Mo¨lndal,
Sweden). Unless otherwise stated, all other chemicals and
reagents were from Sigma.
Plasmid Constructs and Transfection of CHO Cells—The
cDNA of the rat CB1R and EYFP-tagged CB1R (CB1R-EYFP)
were constructed as described previously (9). EYFP-1 was gen-
erated by subcloning human 1 subunit into the mammalian
expression vector pEYFP-C1 (Clontech). o-Rluc was con-
structed by replacing the CFP coding region in o-CFP with
Renilla luciferase. Rat HA-AT1R was constructed as described
earlier (21). CHO cells were maintained in Ham’s F-12 supple-
mented with 10% FBS, 100g/ml streptomycin, and 100 IU/ml
penicillin. For BRET and confocal measurements, cells were
grown in 6-well plates (on glass coverslips for confocal micros-
copy) and transfected with the indicated constructs (2 g of
each DNA) using 2 l/ml Lipofectamine 2000 in Opti-MEM.
Confocal Laser-scanning Microscopy and CB1R Endo-
cytosis—CHO cells were grown on glass coverslips and trans-
fected with CB1R-EYFP 48 h prior to measurement. Cells were
serum-starved for 3 h with or without THL (1 M) prior to
stimulation with WIN55,212-2 (1 M). Following stimulation,
CHO cells were fixed with 4% paraformaldehide and were ana-
lyzed by confocal microscopy in 20 cells in each experiment.
Images were taken approximately at the largest diameter of the
nucleus, with the same settings in all internalization experi-
ments, using a Zeiss LSM 510 confocal laser-scanning micro-
scope. YFP was excited with an argon (488 nm) laser, and emit-
ted fluorescences were detected using a 500–530 bandpass
filter. Membrane and intracellular fluorescence was measured
using ImageJ (W. S. Rasband, ImageJ, United States National
Institutes of Health, Bethesda, MD (rsb.info.nih.gov/ij/) 1997–
2006), andmembrane fluorescence was divided by the intracel-
lular fluorescence. Blind selection and analysis of the cells were
performed to avoid any bias during the evaluation of the inter-
nalization data.
Hippocampal Neuronal Cultures, Transfection, and
Immunocytochemistry—Transfection, immunocytochemistry,
and quantitative imaging of hippocampal neuronal cultures
were performed as described previously (10). Treatments were
identical to those inCHOcells (see above). For quantification of
surface/total ratio of the somatodendritic region, high resolu-
tion images of 14–32 transfected neurons from two independ-
ent experiments were used. In each series, acquisitions were
performed under strictly identical conditions. The somatoden-
dritic compartment was selected on the GFP image (total
CB1R) and themean fluorescence of theGFP and theAlexa-568
(surface CB1R) channels in this region wasmeasured. The ratio
of these two mean fluorescences gave to the surface/total ratio.
BRET Assay—Energy transfer between G protein subunits
was measured using o fused with Renilla luciferase (o-Rluc)
and 1 labeled with EYFP (EYFP-1). Medium was changed to
FBS-supplemented Ham’s F-12 6 h following transfection and
incubated overnight. Before the experiments the cells were
serum-starved for 2 h in the absence or presence of THL, then
detached with Versene and centrifuged. Cells were suspended
in HEPES-buffered F-12 supplemented with 1 g/liter albumin
and transferred to white 96-well plates. Coelenterazine h was
added in HEPES-buffered Ham’s F-12 to a final concentration
of 5 M, and readings were collected using a Mithras LB 940
Multilabel Reader (Berthold Technologies, Bad Wildbad, Ger-
many). The BRET ratio was defined as (emission at 530 nm)/
(emission at 485), and the normalized BRET ratio was calcu-
lated as the BRET ratio for the co-expressed EYFP-1 and
o-Rluc constructs minus the BRET ratio for the co-expressed
non-tagged 1 subunit and o-Rluc constructs. Data are shown
as percent changes in normalized BRET ratios compared with
the mean of the four control BRET ratio points before the first
stimulation (BRET %).
Statistical Analysis—All data are presented as means  S.E.
Differences between groups were analyzed by one- or two-way
repeated measures analysis of variance combined with Holm-
Sidak test using the software SigmaStat forWindows 3.5 (Systat
Software Inc., Richmond, CA). The value of p less than 0.05 was
considered significant.
RESULTS
Measurement of CB1R Activity with BRET—CB1R activity
was measured by energy transfer between heterotrimeric G
protein subunits. CB1R was co-expressed with 11, o-Rluc,
and EYFP-1 subunits in CHO cells. Energy transfer was
detected between o-Rluc and EYFP-1 prior to stimulation, as
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shown in Fig. 1A. Stimulation of cells with WIN55,212-2, a
CB1R agonist, caused a decrease of the BRET signal, indicating
that subunits were dissociated during activation of the hetero-
trimeric Go protein. However, following the addition of
AM251, an inverse agonist, the BRET signal increased, showing
that its change was reversible. In contrast, when the inverse
agonist was added first (Fig. 1A), it increased the BRET signal,
indicating that non-stimulated CB1Rs exert basal activity in
CHO cells. Application of WIN55,212-2 after inverse agonist
treatment caused no decrease in BRET signal, as expected.
Constitutive Activity of CB1R Is Inhibited by DAGL Inhibitor—
The endogenous CB1R agonist 2-AG is generated from DAG by
DAGLs and (18).AsDAGLsare expressed inmost tissues (18),
theymayproduce 2-AG fromDAGinnon-stimulated cells,which
could be responsible for basal CB1R activity. This hypothesis was
tested using THL, a DAGL inhibitor (18, 22). Addition of THL to
cells expressing CB1R andGo protein subunits caused slow eleva-
tion of BRET signal compared with control cells, which indicates
the presence of DAGL-mediated eCB production in CHO cells
(Fig. 1B). Moreover, additional treatment with AM251 caused a
lower BRET ratio elevation compared with control cells but
reached a similar level (Fig. 1B), indicating that the basal activity
was reducedbyTHL.The timecourseof theBRETsignal elevation
could reflect the kinetics of ligand degradation. Addition of
WIN55,212-2 to THL-pretreated cells led to activation of Go pro-
tein (Fig. 1C). However, the inverse agonist effect of AM251 was
much smaller than in cellswithout pretreatment (compare Fig. 1C
with Fig. 1A). The percent changes of the BRET signal following
stimulation are presented in Fig. 1D. AM251 treatment caused a
smaller elevation of BRET ratio in THL-pretreated cells, and, as
expected, the change of BRET ratio followingWIN55,212-2 stim-
ulationwas augmented (Fig. 1D), demonstrating enhancedGpro-
tein activation. These data show that basal Go protein activity was
strongly reduced in THL-pretreated cells, suggesting the role of
DAGL in theconstitutive activityof theCB1R.Similar resultswere
also obtained in HEK-293 cells (data not shown), indicating that
DAGL-dependent constitutive activity is not a CHO cell-specific
mechanism.
THL Pretreatment Leads to Reduced Constitutive Internal-
ization in CHO Cells and Cultured Hippocampal Neurons—
CB1Rs internalize constitutively both in HEK-293 and in
neuronal cells, as described earlier (9, 10). The internaliza-
tion can be further accelerated by agonists, whereas consti-
tutive internalization is inhibited by inverse agonists (9, 23).
The effect of DAGL inhibition by THL treatment was deter-
mined on constitutive internalization. First, CHO cells
transfected with CB1R-EYFP were examined by confocal
microscopy. In agreement with previous data (9), CB1R-
EYFP is localized both to the plasma membrane and to intra-
cellular vesicles in control cells (Fig. 2A), demonstrating that
CB1R internalizes constitutively. 30-min stimulation with 1
M WIN55,212-2 enhanced the endocytosis of the receptor,
as the fluorescence at the plasma membrane decreased,
while more intracellular vesicles appeared (Fig. 2C). In con-
trast, 3-h treatment with THL resulted in CB1R-EYFP trans-
location from vesicles to the plasma membrane (Fig. 2B).
To demonstrate the relevance of this mechanism in pri-
mary cells, we tested the effects of THL treatment in FLAG-
FIGURE 1. CB1R activity measurement with BRET. BRET was measured in
CHO cells expressing the labeled G protein subunits. Control (A) and THL
pretreated (C) cells were treated subsequently with WIN55,212-2 (1 M) and
AM251 (10 M) (filled circles), AM251 (10 M), and WIN55,212-2 (1 M) (open
triangles) orwith vehicle (open square). In B, cells were treatedwith THL (1M)
at 0 time, and AM251 (10 M) was added before the end of experiment. The
statistical analysis was performed frommean BRET% data after the first stim-
ulation, and data are presented on D (**, p 0.01, n 4).
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CB1R-EGFP-transfected primary hippocampal neurons.
Under control conditions, CB1Rs in the somatodendritic
compartment were constitutively internalized, as indicated
by their preferentially intracellular occurrence and the rela-
tively low surface label density (Fig. 2, F and G), in accord-
ance with previous data (10). The THL treatment resulted in
up-regulation of CB1Rs on the somatodendritic cell mem-
brane surface (Fig. 2, H–J).
Although constitutive internalization was inhibited, the
WIN55,212-2 treatment induced similar internalization levels
in control and THL-pretreated CHO cells and in neurons,
showing that the internalization process is not attenuated due
to nonspecific inhibition of endocytosis (Fig. 2, C–E and J).
Angiotensin II (AngII)-induced Activation of CB1Rs—ECB
production in CHO cells has not been observed previously
(14). Therefore, we asked whether extracellular stimuli,
which are expected to lead to DAG production and/or Ca2
signal, can cause activation of expressed CB1Rs. Since Ca2
signal in neuronal tissues leads to eCB production (6), and
CB1R is expressed in many tissues in the cardiovascular sys-
tem (19), we tested whether CB1R activity can be enhanced
by co-expression and stimulation of AT1R, a Gq-activating
GPCR, which has a significant role in cardiovascular regula-
tion (24, 25). Co-expression of AT1R with CB1R and stimu-
lation with AngII caused readily detectable Go activation
(Fig. 3A). The AngII-dependent activation was blocked both
by CB1R inverse agonist (Fig. 3, A and C) and by THL pre-
treatment (Fig. 3, B and C), suggesting that it occurred
through the DAGL-dependent activation of CB1R. The per-
cent changes in BRET signals are shown on Fig. 3C. In con-
trol experiments, stimulation of AT1R, expressed alone with
the Go protein subunits, led to some Go activation (data not
shown); however, this activation was not influenced by THL
or AM251 treatment. Addition of candesartan, an inverse
agonist of AT1R, after AngII stimulation reversed the stim-
ulatory action of AngII. The slow kinetics of candesartan
FIGURE 2. THL induces plasma membrane sequestration of CB1R in CHO
cells andculturedhippocampalneurons.CB1R-EYFPwasexpressed inCHO
cells, and confocal microscopy images were taken of control (A), THL-pre-
treated (B), WIN55,212-2 stimulated (C), and THL pretreated-WIN55,212-2
stimulated (D) cells (n  4–5). THL pretreatment sequesters CB1R on the
plasma membrane but does not inhibit internalization induced by
WIN55,212-2. On E, surface/intracellular fluorescence ratio is shown. FLAG-
CB1R-EGFP was expressed in control (F and G) or THL-pretreated (H and I)
culturedhippocampal neurons. Surface-localizedCB1Rswere detected in live
neurons with M1 anti-FLAG antibody. In control neurons, surface labeling of
the somatodendritic region isweak (G,arrow) comparedwith axons (G,arrow-
head), whereas THL pretreatment up-regulates somatodendritic surface label
(I, arrow). On J, surface/total fluorescence ratio of 14–31 neurons per condi-
tionwas counted from two independent experiments. Scale bar: 25m; *,p
0.05; **, p 0.01.
FIGURE 3.CB1R activitymeasurementwith BRET in CHO cells co-express-
ing CB1R andAT1R. BRETwasmeasured in CHO cells expressing the labeled
G protein subunits. Control (A) and THL-pretreated (B) cells were treated sub-
sequently with AngII (100 nM) and candesartan (1 M) (filled circles), AM251
(10M), and AngII (100 nM) (open triangles) or with vehicle (open square). The
statistical analysis was performed frommean BRET signals after the first stim-
ulation, and data are presented on C. (**, p 0.01, n 3–4).
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action, in contrast to the immediate elevation following
WIN55,212-2 plus AM251 treatment (compare Fig. 3A with
Fig. 1A), is consistent with the higher agonist affinity of the
AT1R. These data suggest that AT1R can transactivate co-
expressed CB1Rs in CHO cells through DAGL-mediated
eCB production.
DISCUSSION
DAGL activity, responsible for 2-AG production, is present
in most tissues (8, 18), and DAG production by phospholipases
C and D is a common process in various cell types. Therefore,
we asked whether the basal DAG production and DAGL activ-
ity can result in sufficient production of cannabinoid agonist(s)
tomaintain the constitutive activity of the CB1R. Here we show
that DAGL inhibition in CHO cells leads to inhibition of the
constitutive activity of CB1R, and similar results were obtained
in HEK-293 cells. Moreover, activation of AT1R, a Gq-activat-
ing GPCR, leads to activation of CB1R. These data suggest that
CHO cells are able to produce a cannabinoid agonist and that
this production occurs in non-stimulated cells and can be
enhanced by AT1R, and presumably other GPCRs, which can
activate Gq. The effect of DAGL inhibition on these processes
suggests that these effects are mediated mainly by 2-AG (26,
27).
Basal CB1R activity has been thought to be agonist-indepen-
dent, based on indirect evidence such as the lack of agonist
production in unstimulated CB1R-expressing cells (8). In con-
trast, our data show that CB1R constitutive activity is, at least in
part, DAGL-dependent. These data are in good agreement with
previous observations, which show that DAGLs are localized in
somatodendritic region of the neurons in adult mouse brain
(18) and CB1Rs internalize constitutively in this region but not
in the axons (10), where the DAGLs are absent. Here we show
that not only tonicGprotein activation but also the constitutive
internalization is inhibited by DAGL inhibitor, both in CHO
cells and in the somatodendritic region of cultured hippocam-
pal neurons. The basal activity of CB1Rs can be further acti-
vated by stimulation of co-expressed Gq-coupled AT1R. Since
the activity depends on endogenous cell-derived ligand(s), it
can indicate continuous regulation of receptor operation,
depending on other membrane receptor activity, phospholipid
turnover, or Ca2-related signals. In cells co-expressing the
CB1R and AT1R, AngII stimulation leads to CB1R activation
through DAGLs, and this could cause initiation of CB1R-spe-
cific signal transduction pathways, which can be different from
those regulated by Gq activation. The CB1R activation after
AngII stimulation is a novel mechanism of AT1R-mediated
receptor transactivation, similar to the transactivation of EGF
and other growth factor receptors reported in various target
tissues of AngII (24).
These data raise the possibility of autocrine regulation of
CB1R constitutive activity and internalization in non-neuronal
tissues and possibly in somatodendritic region of neurons. Such
a mechanism has wide implications for the pharmacological
actions of drugs acting on CB1 receptors in the central nervous
system and the periphery. This type of regulation is in contrast
to the model where CB1R is activated by circulating agonist in
non-neuronal tissues, although the two type of activation could
co-exist.
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